

Anti-CCR5 (Leronlimab), Humanized Antibody

rev 04/21

CATALOG NO.: A2181-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is an investigational humanized IgG4 monoclonal antibody that specifically inhibits CCR5. CCR5 is a chemokine receptor that is expressed on the surface of a broad range of cells including T-cells, B-cells, and macrophages, and plays an important role in immune responses. Human Immunodeficiency Virus 1 (HIV-1) uses CCR5 as a co-receptor to enter and infect immunologic cells. The antibody binds to the hydrophilic extracellular domains of the CCR5 and competitively inhibits the CCR5-mediated HIV-1 entry into the host cells. The antibody does not target viruses using CXCR4 as a receptor to enter host cells. The original drug was granted Fast Track Designation by the US FDA to treat HIV infected patients in combination with HAART, and for metastatic triple-negative breast cancer. Currently, the drug is in early clinical trials to treat COVID-19 disease.

ALTERNATE NAMES: PA14, PRO 140, PRO-140, PRO140, HuPRO-140, CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CCR5

CAS NUMBER: 674782-26-4

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)
 Anti-IL-1 β (Canakinumab), Human IgG1 Antibody (A2144)
 Anti-CD6 (Itolizumab), Humanized Antibody (A2164)
 Anti-IL-17 α (Ixekizumab), Humanized Antibody (A2149)

FOR RESEARCH USE ONLY! Not to be used on humans.